Management of calcified cysticerci in the brain parenchyma: treating the dead parasite

被引:0
作者
Del Brutto, Oscar H. [1 ]
机构
[1] Univ Espiritu St Ecuador, Sch Med & Res Ctr, Samborondon, Ecuador
关键词
Bisphosphonates; breakthrough seizures; calcifications; calcitonin gen-related peptide; chronic headaches; cysticercosis; hippocampal atrophy; neurocysticercosis; TEMPORAL-LOBE EPILEPSY; HIPPOCAMPAL SCLEROSIS; PERILESIONAL EDEMA; SEIZURE RECURRENCE; PROSPECTIVE COHORT; NEUROCYSTICERCOSIS; CALCIFICATIONS; ATROPHY; LESIONS; ASSOCIATION;
D O I
10.1080/14787210.2024.2409404
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
IntroductionCalcifications are the end stage of many parenchymal brain cysticerci and may occur either spontaneously or as the result of treatment with cysticidal drugs. These lesions, traditionally considered inert and asymptomatic, have been associated with several complications that seem to be mostly related to brain damage and inflammation ensuing as the result of the exposure of the host's immune system to parasitic antigens trapped within calcifications.Areas coveredThis review, based on the search of different electronic databases up to May 2024, focuses on the reported correlates and complications of calcified cysticerci (chronic headaches, seizures/epilepsy, hippocampal atrophy/sclerosis, gliomas), and the different interventions developed for their prevention and treatment. Common analgesics, non-steroidal anti-inflammatory drugs, corticosteroids, and antiseizure medications have been used with success but, with the exception of the latter, these drugs offer temporary relief of symptoms and support for their use is based on level 3 evidence.Expert opinionSeveral strategies may reduce the severity of clinical consequences of calcified cysticerci. Probably, the most relevant intervention would be the prevention of their occurrence or reduction in their size. In this view, the use of bisphosphonates appears as a potential option that needs to be tested in humans.
引用
收藏
页码:1073 / 1084
页数:12
相关论文
共 104 条
[11]  
Bianchin MM, 2005, EPILEPSIA, V46, P236
[12]   Breakthrough seizures-Further analysis of the Standard versus New Antiepileptic Drugs (SANAD) study [J].
Bonnett, Laura J. ;
Powell, Graham A. ;
Smith, Catrin Tudur ;
Marson, Anthony G. .
PLOS ONE, 2017, 12 (12)
[13]   The Migraine Attack as a Homeostatic, Neuroprotective Response to Brain Oxidative Stress: Preliminary Evidence for a Theory [J].
Borkum, Jonathan M. .
HEADACHE, 2018, 58 (01) :118-135
[14]   Epilepsy and Neurocysticercosis in Latin America: A Systematic Review and Meta-analysis [J].
Bruno, Elisa ;
Bartoloni, Alessandro ;
Zammarchi, Lorenzo ;
Strohmeyer, Marianne ;
Bartalesi, Filippo ;
Bustos, Javier A. ;
Santivanez, Saul ;
Garcia, Hector H. ;
Nicoletti, Alessandra .
PLOS NEGLECTED TROPICAL DISEASES, 2013, 7 (10)
[15]   Frequency and Determinant Factors for Calcification in Neurocysticercosis [J].
Bustos, Javier A. ;
Arroyo, Gianfranco ;
Gilman, Robert H. ;
Soto-Becerra, Percy ;
Gonzales, Isidro ;
Saavedra, Herbert ;
Pretell, E. Javier ;
Nash, Theodore E. ;
O'Neal, Seth E. ;
Del Brutto, Oscar H. ;
Gonzalez, Armando E. ;
Garcia, Hector H. .
CLINICAL INFECTIOUS DISEASES, 2021, 73 (09) :E2592-E2600
[16]   Brain calcification because of neurocysticercosis: a vast field to be explored [J].
Bustos, Javier A. ;
Coyle, Christina M. .
CURRENT OPINION IN INFECTIOUS DISEASES, 2020, 33 (05) :334-338
[17]   Antiepileptic drug therapy and recommendations for withdrawal in patients with seizures and epilepsy due to neurocysticercosis [J].
Bustos, Javier A. ;
Garcia, Hector H. ;
Del Brutto, Oscar H. .
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (09) :1079-1085
[18]  
Carpio Arturo, 2013, Neurol Clin Pract, V3, P118
[19]  
Chung C K, 1998, J Korean Med Sci, V13, P445
[20]   HEADACHE AND CYSTICERCOSIS IN ECUADOR, SOUTH-AMERICA [J].
CRUZ, ME ;
CRUZ, I ;
PREUX, PM ;
SCHANTZ, P ;
DUMAS, M .
HEADACHE, 1995, 35 (02) :93-97